

CLAIMS

1. P2X7 purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis, in mammals including man characterised in that the antagonist is selected among Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP or HMA.
5
2. P2X7 purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with claim 1 characterised in that the antagonist is o-ATP.
10
3. Use of an antagonist of P2X7 purinergic receptors in the preparation of a drug for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis, in mammals including man characterised in that antagonist is selected among Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP or HMA.
15
4. Use of an antagonist of P2X7 purinergic receptors in accordance with claim 3 characterised in that the antagonist is o-ATP.
20
5. A pharmaceutical composition which comprises at least one P2X7 purinergic receptor antagonist and at least one pharmaceutically acceptable excipient characterised in that antagonist is selected among Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP or HMA. .
25
6. A pharmaceutical composition in accordance with claim 5 characterised in that the antagonist is o-ATP